Wall Street Icon: “You must get on the right side of this thing”

I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.

This market shakeup is going to be much more intense.

Andrew Fenton Biography and Net Worth

EVP of Zoetis

Mr. Andrew Fenton has been Chief Information Officer and Executive Vice President of Zoetis Inc. since August 23, 2016. Mr. Fenton is responsible for leading a global Information Technology Services (ITS) team that supports the business performance, efficiency and customer experiences for this $4.8 billion company. Prior to joining Zoetis in 2014, Mr. Fenton was a Partner and Principal of EY in the Life Sciences practice supporting CIO Transformation Services. Mr. Fenton served as Senior Vice President of Warner Chilcott plc since January 2012 and served as its Chief Information Officer. With more than 25 years of experience in life sciences and information technology, Mr. Fenton has held several positions in the pharmaceutical industry, with increasing responsibility for planning and IT infrastructure to support manufacturing plants and large-scale technology transformation programs, including SAP. Mr. Fenton served as Vice President and Chief Information Officer of Warner Chilcott Corporation. He was instrumental in building an IT organization and driving shareholder value at Warner Chilcott. Mr. Fenton joined Warner Chilcott on November 28, 2005. He served as Vice President of Global Relationship Partner of IBM Corporation for 3 years. Mr. Fenton served positions at PricewaterhouseCoopers Consulting, serving as a Senior Partner in the Pharmaceutical Practice and served several positions in the pharmaceutical industry spanning areas of responsibility such as manufacturing, supply-chain management, operations and engineering. Mr. Fenton graduated from BCIT - British Columbia in Canada, with a focus on Operations Management and Information Technology.

What is Andrew Fenton's net worth?: The estimated net worth of Andrew Fenton is at least $3.55 million as of November 21st, 2019. Mr. Fenton owns 21,530 shares of Zoetis stock worth more than $3,549,005 as of December 22nd. This net worth evaluation does not reflect any other assets that Mr. Fenton may own. Learn More about Andrew Fenton's net worth.
How do I contact Andrew Fenton?: The corporate mailing address for Mr. Fenton and other Zoetis executives is 10 Sylvan Way, Parsippany NJ, 07054. Zoetis can also be reached via phone at (973) 822-7000 and via email at [email protected]. Learn More on Andrew Fenton's contact information.
Has Andrew Fenton been buying or selling shares of Zoetis?: Andrew Fenton has not been actively trading shares of Zoetis during the last ninety days. Most recently, Andrew Fenton sold 12,705 shares of the business's stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $120.30, for a transaction totalling $1,528,411.50. Following the completion of the sale, the executive vice president now directly owns 21,530 shares of the company's stock, valued at $2,590,059. Learn More on Andrew Fenton's trading history.
Who are Zoetis' active insiders?: Zoetis' insider roster includes Juan Alaix (Director), Heidi Chen (EVP), Glenn David (EVP), Andrew Fenton (EVP), Wetteny Joseph (Exec. VP & CFO ), Robert Kelly (EVP), Catherine Knupp (EVP), Roxanne Lagano (EVP), Clinton Lewis, Jr. (EVP), Gregory Norden (Director), Kristin Peck (CEO & Director), Robert Polzer (EVP), Willie Reed (Director), Linda Rhodes (Director), Robert Scully (Director), and Roman Trawicki (EVP). Learn More on Zoetis' active insiders.
Are insiders buying or selling shares of Zoetis?: In the last twelve months, insiders at the sold shares 4 times. They sold a total of 3,132 shares worth more than $547,983.01. The most recent insider tranaction occured on April, 18th when EVP Roxanne Lagano sold 923 shares worth more than $139,529.91. Insiders at Zoetis own 0.2% of the company. Learn More about insider trades at Zoetis.
Information on this page was last updated on 4/18/2024.

Andrew Fenton Insider Trading History at Zoetis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/21/2019	Sell	12,705	$120.30	$1,528,411.50	21,530
9/2/2016	Sell	13,870	$51.25	$710,837.50	17,719

Andrew Fenton Buying and Selling Activity at Zoetis

Zoetis Company Overview

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Today's Range

Now: $164.84

$163.53

$166.39

50 Day Range

MA: $178.52

$163.52

$194.45

2 Week Range

Now: $164.84

$144.80

$200.53

Volume

6,184,068 shs

Average Volume

2,552,173 shs

Market Capitalization

$74.37 billion

P/E Ratio

30.99

Dividend Yield

1.03%

Beta

0.89